Почетна › Difuzni veliki B-ćelijski limfom › Северна Каролина
Kliničke studije za Difuzni veliki B-ćelijski limfom u državi Северна Каролина
20 studija za Difuzni veliki B-ćelijski limfom traži učesnike na lokacijama u državi Северна Каролина.
Gradovi u državi Северна Каролина
Zvanični tekst studije (na engleskom)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- East Carolina University ( Site 0159), Greenville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of North Carolina Medical Center ( Site 0136), Chapel Hill
- Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
- Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Duke University Medical Center, Durham
- East Carolina University, Greenville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06091865A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07188558A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07691606Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Novant Health Cancer Institute- Hematology, Charlotte
- Duke Blood Cancer Center, Durham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06500273Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 28. 10. 2026. · NCT01137643Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Wake Forest University Health Sciences, Winston-Salem
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06015880Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Duke University Medical Center, Durham
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05633615Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT05826535Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 5. 8. 2026. · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 7. 2026. · NCT05131022Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- и још 4
Тражи се учесникОпсервациона студија
Узраст 65 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT01137825Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT04775745A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2025. · NCT05107674Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 9. 2024. · NCT06238648DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Brody School of Medicine at East Carolina University, Greenville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 4. 2023. · NCT04920617Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.